Search Results

Raltitrexed: optimism and reality

Authors: Wilson, Kenneth S; Malfair Taylor, Suzanne C

Source: Expert Opinion on Drug Metabolism and Toxicology, Volume 5, Number 11, November 2009 , pp. 1447-1454(8)

Publisher: Informa Healthcare

Chronic myeloid leukemia following the treatment of rectal adenocarcinoma

Authors: Kadikoylu, Gurhan; Yavasoglu, Irfan; Barutca, Sabri; Meydan, Nezih; Bolaman, Zahit

Source: Medical Oncology, Volume 25, Number 4, December 2008 , pp. 467-470(4)

Publisher: Humana Press

Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes

Authors: Sienkiewicz, Natasha; Jarosławski, Szymon; Wyllie, Susan; Fairlamb, Alan H.

Source: Molecular Microbiology, Volume 69, Number 2, July 2008 , pp. 520-533(14)

Publisher: Blackwell Publishing

Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part II

Authors: Gangjee, Aleem; Jain, Hiteshkumar D.; Kurup, Sonali

Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry, Volume 8, Number 2, February 2008 , pp. 205-231(27)

Publisher: Bentham Science Publishers

Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience

Authors: Wilson, Kenneth; Fitzgerald, Catherine; Barnett, Jeff; Pharm, B.; Gill, Sharlene; Khoo, Kong

Source: Cancer Investigation, Volume 25, Number 8, October 2007 , pp. 711-714(4)

Publisher: Informa Healthcare

Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part I

Authors: Gangjee, Aleem; Jain, Hiteshkumar D.; Kurup, Sonali

Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry, Volume 7, Number 5, September 2007 , pp. 524-542(19)

Publisher: Bentham Science Publishers

Cost Considerations in the Treatment of Colorectal Cancer

Authors: Jansman, Frank G.A.; Postma, Maarten J.; Brouwers, Jacobus R.B.J.

Source: PharmacoEconomics, Volume 25, Number 7, 2007 , pp. 537-562(26)

Publisher: Adis International

A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer

Authors: Krol, Marieke; Koopman, Miriam; Uyl-de Groot, Carin; Punt, Cornelis JA

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 9, June 2007 , pp. 1313-1328(16)

Publisher: Informa Healthcare

Antineoplastics/folinic acid: Facial skin and parotid gland metastases in an elderly patient receiving radiotherapy: case report

Source: Reactions, Volume 1, Number 1158, 2007-06-30 , pp. 8-8(1)

Publisher: Adis International

Management Options for Malignant Pleural Mesothelioma: Clinical and Cost Considerations

Author: Goudar, Ranjit K.

Source: Drugs, Volume 67, Number 8, 2007 , pp. 1149-1165(17)

Publisher: Adis International

Molecular basis of antifolate resistance

Author: Assaraf, Yehuda

Source: Cancer and Metastasis Reviews, Volume 26, Number 1, March 2007 , pp. 153-181(29)

Publisher: Springer

An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed

Authors: Graham-Cole, Claire; Thomas, Huw; Taylor, Gordon; Newell, David; Melton, Roger; Hesp, Richard; Boddy, Alan

Source: Cancer Chemotherapy and Pharmacology, Volume 59, Number 2, February 2007 , pp. 197-206(10)

Publisher: Springer

Antisense Targeting of Thymidylate Synthase (TS) mRNA Increases TS Gene Transcription and TS Protein: Effects on Human Tumor Cell Sensitivity to TS Enzyme-Inhibiting Drugs

Authors: JASON, TRACEY L. H.; BERG, RANDAL W.; VINCENT, MARK D.; KOROPATNICK, JAMES

Source: Gene Expression, Volume 13, Numbers 4-5, 2006 , pp. 227-239(13)

Publisher: Cognizant Communication Corporation

Oxaliplatin/raltitrexed: Enterocolitis (first report) in elderly patients: 2 case reports

Source: Reactions, Volume 1, Number 1122, 2006-10-07 , pp. 17-18(2)

Publisher: Adis International

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer

Authors: Masi, G.; Marcucci, L.; Loupakis, F.; Cerri, E.; Barbara, C.; Bursi, S.; Allegrini, G.; Brunetti, I. M.; Murr, R.; Ricci, S.; Cupini, S.; Andreuccetti, M.; Falcone, A.

Source: Annals of Oncology, Volume 17, Number 8, August 2006 , pp. 1249-1254(6)

Publisher: Oxford University Press

Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas

Authors: Gebbia, V.; Verderame, F.; Ferraù, F.; Bordonaro, R.; Callari, A.; Caruso, M.; Tirrito, M. L.; Valenza, R.; Cicero, G.; Borsellino, N.; Tralongo, P.

Source: Annals of Oncology, Volume 17, Supplement 1, June 2006 , pp. vii60-vii65(1)

Publisher: Oxford University Press

Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

Authors: Cao, Shousong; Bhattacharya, Arup; Durrani, Farukh A; Fakih, Marwan

Source: Expert Opinion on Pharmacotherapy, Volume 7, Number 6, 1 April 2006 , pp. 687-703(17)

Publisher: Informa Healthcare

Raltitrexed + cisplatin stabilise HRQOL in mesothelioma

Source: Inpharma, Volume 1, Number 1530, 2006-03-25 , pp. 11-11(1)

Publisher: Adis International

Raltitrexed + cisplatin improves survival with stable HRQOL in mesothelioma

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 498, 2006-03-11 , pp. 9-9(1)

Publisher: Adis International

Antimetabolites and cancer: emerging data with a focus on antifolates

Authors: Scagliotti, Giorgio V; Selvaggi, Giovanni

Source: Expert Opinion on Therapeutic Patents, Volume 16, Number 2, 1 February 2006 , pp. 189-200(12)

Publisher: Informa Healthcare